<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Irinotecan (conventional): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Irinotecan (conventional): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Irinotecan (conventional): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10886" href="/d/html/10886.html" rel="external">see "Irinotecan (conventional): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13238" href="/d/html/13238.html" rel="external">see "Irinotecan (conventional): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708954"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Diarrhea:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life-threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan and reduce subsequent doses if severe diarrhea occurs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Severe myelosuppression may occur.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F184455"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Camptosar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867255"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Camptosar [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F184493"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Camptothecin;</li>
<li>
                        Antineoplastic Agent, Topoisomerase I Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F184460"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> A reduction in the starting dose by at least 1 dose level should be considered for prior pelvic/abdominal radiotherapy or performance status of 2 (subsequent dosing/adjustments should be based on individual tolerance). Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Reduced UGT1A1 activity:</i></b>Consider a dose reduction in the starting irinotecan dose by at least 1 dose level for patients known to be homozygous for the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or compound heterozygous for the UGT1A1*28 and *6 alleles (*6/*28); base subsequent dosing modifications on individual tolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Premedications:</i></b> Consider premedication of atropine 0.25 to 1 mg IV or SubQ in patients with cholinergic symptoms (eg, increased salivation, rhinitis, miosis, diaphoresis, abdominal cramping) or early-onset diarrhea. Irinotecan is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="15250d94-cf6f-4b85-9d46-2215f76ae348">Colorectal cancer, metastatic, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic, combination therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>In combination with fluorouracil and leucovorin: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Regimen 1: <b>IV:</b> 125 mg/m<sup>2</sup> over 90 minutes on days 1, 8, 15, and 22 of a 6-week cycle (in combination with bolus leucovorin and fluorouracil; leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin); continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">Adjusted dose level −1: 100 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adjusted dose level −2: 75 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Further adjust if needed in decrements of ~20%.</p>
<p style="text-indent:-2em;margin-left:6em;">Regimen 2 (FOLFIRI regimen): <b>IV:</b> 180 mg/m<sup>2</sup> over 90 minutes on days 1, 15, and 29 of a 6-week cycle (in combination with infusional leucovorin and bolus/infusion fluorouracil; leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin); continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">Adjusted dose level −1: 150 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adjusted dose level −2: 120 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Further adjust if needed in decrements of ~20%.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>FOLFIRI regimens may also be administered in combination with bevacizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17947725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17947725'])">Ref</a></span>), cetuximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19339720','lexi-content-ref-21502544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19339720','lexi-content-ref-21502544'])">Ref</a></span>), panitumumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20921462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20921462'])">Ref</a></span>), ramucirumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25877855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25877855'])">Ref</a></span>), or ziv-aflibercept (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949147'])">Ref</a></span>); refer to protocols for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>FOL</b>
<b>FOXIRI regimen (off-label dosing):</b>
<b>IV:</b> 165 mg/m<sup>2</sup> over 1 hour once every 2 weeks (in combination with oxaliplatin, leucovorin, and fluorouracil); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470860'])">Ref</a></span>) <b>or</b> 165 mg/m<sup>2</sup> over 1 hour once every 2 weeks (in combination with oxaliplatin, leucovorin, fluorouracil, and bevacizumab) for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26338525','lexi-content-ref-25337750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26338525','lexi-content-ref-25337750'])">Ref</a></span>) <b>or </b>150 mg/m<sup>2</sup> over 1 hour once every 14 days (in combination with oxaliplatin, leucovorin, fluorouracil, and panitumumab) until disease progression or resection for up to a maximum of 12 preoperative cycles; after resection, patients received the same regimen as adjuvant therapy for a total of 12 perioperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31609637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31609637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>In combination with cetuximab (off-</b>
<b>label combination): IV: </b>180 mg/m<sup>2</sup> over 30 minutes once every 2 weeks (in combination with cetuximab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18281264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18281264'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51c67809-0202-49b4-b14b-33ab4b49781a">Colorectal cancer, metastatic, single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic, single-agent therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Weekly regimen:<b> IV:</b> 125 mg/m<sup>2</sup> over 90 minutes on days 1, 8, 15, and 22 of a 6-week treatment cycle (may adjust upward to 150 mg/m<sup>2</sup> if tolerated); continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">Adjusted dose level −1: 100 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adjusted dose level −2: 75 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">Further adjust to 50 mg/m<sup>2</sup> (in decrements of 25 to 50 mg/m<sup>2</sup>) if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Once-every-3-week regimen: <b>IV:</b> 350 mg/m<sup>2</sup> over 90 minutes, once every 3 weeks; continue until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">Adjusted dose level −1: 300 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adjusted dose level −2: 250 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">Further adjust to 200 mg/m<sup>2</sup> (in decrements of 25 to 50 mg/m<sup>2</sup>) if needed</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abc28755-296d-44c6-8865-b968961e4811">Cervical cancer, recurrent or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, recurrent or metastatic (off-label use):</b>
<b>IV:</b> 125 mg/m<sup>2</sup> over 90 minutes once weekly for 4 consecutive weeks followed by a 2-week rest during each 6-week treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9053486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9053486'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f49f401d-abed-4de8-9502-8e61191f37c7">CNS tumor, recurrent glioblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS tumor, recurrent glioblastoma (off-label use):</b>
<b>IV:</b> 125 mg/m<sup>2</sup> over 90 minutes once every 2 weeks (in combination with bevacizumab); continue for up to 2 years or until disease progression or unacceptable toxicity. <b>NOTE:</b> In the studies, the irinotecan dose was increased in patients taking concurrent antiseizure enzyme-inducing medications; refer to protocols for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19720927','lexi-content-ref-17947719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19720927','lexi-content-ref-17947719'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2dc4466-b953-4553-9c6b-debc154d6649">Esophageal cancer, metastatic or locally advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, metastatic or locally advanced (off-label use):</b>
<b>IV:</b> 65 mg/m<sup>2</sup> over 90 minutes days 1, 8, 15, and 22 of a 6-week treatment cycle (in combination with cisplatin); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11857295','lexi-content-ref-10506629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11857295','lexi-content-ref-10506629'])">Ref</a></span>) <b>or</b> 180 mg/m<sup>2</sup> over 90 minutes every 2 weeks (in combination with leucovorin and fluorouracil); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25287828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25287828'])">Ref</a></span>) <b>or</b> 250 mg/m<sup>2</sup> every 3 weeks (in combination with capecitabine) for up to a maximum of 24 weeks or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19104814','lexi-content-ref-19605504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19104814','lexi-content-ref-19605504'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="130c3e8f-5b0a-41a6-a1bc-76e68507c424">Ewing sarcoma, recurrent or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma, recurrent or progressive (off-label use):</b>
<b>IV:</b> 20 mg/m<sup>2</sup> days 1 to 5 and days 8 to 12 every 3 weeks (in combination with temozolomide); continue for up to 12 cycles (patients received a median of 7.5 cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19637327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19637327'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51e73bfa-57d3-4ff4-aaa8-0c2db9cf016a">Gastric cancer, metastatic or locally advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, metastatic or locally advanced (off-label use):</b>
<b>IV:</b> 150 mg/m<sup>2</sup> (as a single agent) on days 1 and 15 of a 4-week treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24190112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24190112'])">Ref</a></span>) <b>or</b> 65 mg/m<sup>2</sup> over 90 minutes days 1, 8, 15, and 22 of a 6-week treatment cycle (in combination with cisplatin); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11857295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11857295'])">Ref</a></span>) <b>or</b> 70 mg/m<sup>2</sup> over 90 minutes on days 1 and 15 of a 4-week treatment cycle (in combination with cisplatin) for up to 6 cycles (or until disease progression or unacceptable toxicity are detected) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15930889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15930889'])">Ref</a></span>) <b>or</b> 180 mg/m<sup>2</sup> over 90 minutes every 2 weeks (in combination with leucovorin and fluorouracil); continue for at least 4 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15514373','lexi-content-ref-25287828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15514373','lexi-content-ref-25287828'])">Ref</a></span>) <b>or</b> 250 mg/m<sup>2</sup> every 3 weeks (in combination with capecitabine); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19605504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19605504'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad194d3d-afa9-45ac-adf1-d7dea803df96">Non–small cell lung cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, advanced (off-label use):</b>
<b>IV:</b> 60 mg/m<sup>2</sup> days 1, 8, and 15 every 4 weeks (in combination with cisplatin); continue for 3 or more cycles until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17079694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17079694'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="479ef10a-6b2a-4e53-99cb-72b1c9e69432">Ovarian cancer, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, recurrent (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Platinum- and taxane-resistant</i>: <b>IV:</b> 100 mg/m<sup>2</sup> days 1, 8, and 15 every 4 weeks (as a single-agent) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16298422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16298422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Platinum-</i>
<i>refractory/resistant: </i>
<b>IV: </b>Initial: 50 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with gemcitabine) until disease progression or unacceptable toxicity; chemotherapy doses were modified based on the presence or absence of toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33185049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33185049'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2ef5d06-eb08-4064-9765-eeb1fa388d2e">Pancreatic cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, advanced or metastatic (off-label use):</b> FOLFIRINOX regimen: <b>IV:</b> 180 mg/m<sup>2</sup> over 90 minutes every 2 weeks (in combination with oxaliplatin, leucovorin, and fluorouracil) until disease progression or unacceptable toxicity (12 cycles were recommended in patients who responded) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15718320','lexi-content-ref-21561347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15718320','lexi-content-ref-21561347'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a39e464-8bb6-4795-a1b3-a3b1646f0ac0">Pancreatic cancer, potentially curable, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, potentially curable, adjuvant therapy (off-label use):</b>
<b>Note:</b> American Society of Clinical Oncology (ASCO) guidelines recommend 6 months of adjuvant therapy if recovery is complete; if preoperative chemotherapy therapy was received, a total of 6 months of adjuvant therapy (including the preoperative regimen) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFIRINOX regimen: </i>
<b>IV:</b> 150 mg/m<sup>2</sup> every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin; modified FOLFIRINOX regimen) for 24 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575490'])">Ref</a></span>). According to ASCO guidelines, mFOLFIRINOX is the preferred first-line adjuvant regimen for potentially curable disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>)<i>.</i></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31c48f83-bf58-4284-88fa-2ba7327a791c">Rhabdomyosarcoma, metastatic or relapsed/progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma, metastatic or relapsed/progressive (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adults &lt;50 years of age: <b>IV:</b> 50 mg/m<sup>2</sup> (maximum: 100 mg/dose) once daily for 5 days during protocol-specific weeks (in combination with ifosfamide, etoposide, vincristine, doxorubicin, cyclophosphamide, dactinomycin, and radiation; high-risk disease); protocol-specific weeks assigned were weeks 1, 4, 20, 23, 47, and 50 (refer to protocol for details) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26503200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26503200'])">Ref</a></span>). In adult patients &lt;21 years of age, may consider the regimen below.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults &lt;21 years of age: <b>IV:</b> 50 mg/m<sup>2</sup> once daily for 5 days at weeks 1 and 4 (in combination with vincristine); if complete or partial response occurs, continue 50 mg/m<sup>2</sup> once daily for 5 days at weeks 13, 25, 34, 46, and 49 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20837952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20837952'])">Ref</a></span>). Refer to protocol for details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80e1258c-674d-41d4-a1b2-d3be69bcf8cf">Small bowel adenocarcinoma, advanced unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small bowel adenocarcinoma, advanced unresectable or metastatic (off-label use): Note: </b>Ampullary adenocarcinomas were excluded from this study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21425142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21425142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen (following progression on a platinum-based regimen): </i>
<b>IV: </b>180 mg/m<sup>2</sup> over 90 minutes once every 2 weeks (in combination with leucovorin and fluorouracil); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21425142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21425142'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c88caf76-c889-4e40-ac97-066402923404">Small cell lung cancer, extensive stage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, extensive stage (off-label use):</b>
<b>IV:</b> 60 mg/m<sup>2</sup> days 1, 8, and 15 every 4 weeks (in combination with cisplatin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11784874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11784874'])">Ref</a></span>) <b>or</b> 65 mg/m<sup>2</sup> days 1 and 8 every 3 weeks (in combination with cisplatin) for a minimum of 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16648503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16648503'])">Ref</a></span>) <b>or</b> 175 mg/m<sup>2</sup> day 1 every 3 weeks for 4 cycles (in combination with carboplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18779613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18779613'])">Ref</a></span>) <b>or</b> 50 mg/m<sup>2</sup> days 1, 8 and 15 every 4 weeks (in combination with carboplatin); in the study, patients received a median of 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16423848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16423848'])">Ref</a></span>). According to ASCO guidelines, platinum-based therapy (cisplatin or carboplatin) in combination with either etoposide or irinotecan for 4 to 6 cycles is recommended over other regimens for extensive stage disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ea69b58-37e1-4093-b913-1a5015679dcf">Small cell lung cancer, limited stage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, limited stage (off-label use):</b> Consolidation therapy (administer after induction cisplatin, etoposide, and radiation therapy): <b>IV:</b> 60 mg/m<sup>2</sup> days 1, 8, and 15 every 3 to 4 weeks (in combination with cisplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24309370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24309370'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abf998a3-72fe-40c4-a3e9-57f7fa6c7507">Unknown primary adenocarcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary adenocarcinoma (off-label use): IV:</b> 100 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with gemcitabine) for 4 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20164695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20164695'])">Ref</a></span>) <b>or</b> 60 mg/m<sup>2</sup> on days 1, 8, and 15 every 4 weeks (in combination with carboplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19088717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19088717'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990697"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Irinotecan clearance is complex with extensive interpatient variability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29520731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29520731'])">Ref</a></span>); kidney function is one consideration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37337890','lexi-content-ref-23536639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37337890','lexi-content-ref-23536639'])">Ref</a></span>) in the context of additional factors influencing drug disposition and toxicity (eg, liver function, <i>UGT1A1</i> genotype, liver function, concurrent medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29520731','lexi-content-ref-34703007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29520731','lexi-content-ref-34703007'])">Ref</a></span>). Monitor patients with kidney impairment closely for development of toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;60 mL/minute: Consider initiating with 75% to 100% of the usual indication-specific dose; if starting with a reduced dose, increase if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1','lexi-content-ref-37337890','lexi-content-ref-18288083','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1','lexi-content-ref-37337890','lexi-content-ref-18288083','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Although the clearance of irinotecan in these patients appears unaltered, unbound fraction may be increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26337772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26337772'])">Ref</a></span>). Additionally, a retrospective study in which patients received 350 mg/m<sup>2</sup> irinotecan every 3 weeks found a 2.5-times higher risk of grade 3 or 4 neutropenia in patients with CrCl 35 to 66 mL/minute compared to patients with CrCl &gt;98 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18288083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18288083'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Consider initiating with 50% to 66% of the usual indication-specific dose; increase if tolerated; use with caution. The unbound AUC of SN-38 (active metabolite) is increased 4.4-fold potentially due to reduced nonrenal metabolism, and adverse effects are more likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37337890','lexi-content-ref-19193575','lexi-content-ref-26337772','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37337890','lexi-content-ref-19193575','lexi-content-ref-26337772','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18288083','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18288083','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Irinotecan may be partially dialyzable, SN38 (active metabolite) is not (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193575','lexi-content-ref-17667606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193575','lexi-content-ref-17667606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> The manufacturer does not recommend use and some studies suggest higher risk of toxicity in patients with end-stage kidney disease (ESKD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214'])">Ref</a></span>). <b>Initial:</b> If benefits outweigh the risks may initiate with 50% to 66% of the usual recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>) <b>or</b> given the variability in patient response, when the usual indication-specific dose is 100 to 150 mg/m<sup>2</sup> once weekly, it may be safest to reduce the dose to 50 mg/m<sup>2</sup> once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-11893885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-11893885'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Doses may be increased with caution if tolerated; severe toxicity at 80 mg/m<sup>2</sup> weekly (grade 4 neutropenia and death in a patient with <i>UGT1A</i> polymorphism) and 100 mg/m<sup>2</sup> weekly (grade 4 diarrhea) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21617725','lexi-content-ref-11893885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21617725','lexi-content-ref-11893885'])">Ref</a></span>). Administer after hemodialysis or on nondialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> The manufacturer does not recommend use and some studies suggest higher risk of toxicity in patients with ESKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-11893885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-11893885'])">Ref</a></span>). <b>Initial:</b> If benefits outweigh the risks may initiate with 50% to 66% of the usual recommended dose <b>or</b> when the usual indication-specific dose is 100 to 150 mg/m<sup>2</sup> once weekly, it may be safest to reduce the dose to 50 mg/m<sup>2</sup> once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Doses may be increased with caution if tolerated; severe toxicity at 80 mg/m<sup>2</sup> weekly (grade 4 neutropenia and death in a patient with <i>UGT1A </i>polymorphism) and 100 mg/m<sup>2</sup> weekly (grade 4 diarrhea) has been reported in patients with ESKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21617725','lexi-content-ref-11893885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21617725','lexi-content-ref-11893885'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions (eg, diarrhea, myelosuppression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Dose as for CrCl &lt;30 mL/minute; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions (eg, diarrhea, myelosuppression) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Dose as for CrCl &lt;30 mL/minute; use with caution. When scheduled dose falls on PIRRT days, dose after PIRRT or on non-PIRRT days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988023"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Manufacturer's labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Liver metastases with normal hepatic function: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin &gt;ULN to ≤2 mg/dL: Consider reducing initial dose by 1 dose level.</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin &gt;2 mg/dL: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Alternate recommendations: </i>The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin 1.5 to 3 mg/dL: Administer 75% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bilirubin 1.51 to 3 times ULN: Reduce dose from 350 mg/m<sup>2</sup> every 3 weeks to 200 mg/m<sup>2</sup> every 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12409328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12409328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weekly irinotecan dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin 1.5 to 3 times ULN and ALT/AST ≤5 times ULN <b>or</b> bilirubin ≤1.5 times ULN and ALT/AST &gt;5 to 20 times ULN: Administer 60 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin &gt;3 to 5 times ULN and ALT/AST ≤5 times ULN: Administer 50 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Bilirubin 1.5 to 3 times ULN and ALT/AST &gt;5 to 20 times ULN: Administer 40 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F20342063"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate chemotherapy dosing in adults with cancer with </i>
<i>a BMI ≥30 kg/m<sup>2</sup></i>
<i>: </i>Utilize patient's actual body weight (full weight) for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F184494"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">It is recommended that new courses begin only after the granulocyte count recovers to ≥1,500/mm<sup>3</sup>, platelets recover to ≥100,000/mm<sup>3</sup>, and treatment-related diarrhea has fully resolved. Depending on the patient's ability to tolerate therapy, doses should be adjusted in increments of 25 to 50 mg/m<sup>2</sup>. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consider discontinuing irinotecan. See tables.</p>
<table border="1" data-table-id="campsing" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colorectal Cancer: Single-Agent Schedule: Recommended Dosage Modifications<sup>a</sup></b></caption>
<colgroup><col/>
<col/>
<col/>
<col/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Toxicity grade (value)</p></th>
<th align="center">
<p style="text-indent:0em;">During a cycle of therapy</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">At start of subsequent cycles of therapy (after adequate recovery), compared to starting dose in previous cycle<sup>a</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Weekly</p></th>
<th align="center">
<p style="text-indent:0em;">Weekly</p></th>
<th align="center">
<p style="text-indent:0em;">Once every 3 weeks</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="top">
<p style="text-indent:0em;">
<sup>a </sup>All dose modifications should be based on the worst preceding toxicity.</p></td></tr>
<tr>
<td align="left" colspan="4" valign="top">
<p style="text-indent:0em;">
<sup>b </sup>Excludes alopecia, anorexia, asthenia.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">No toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">↑ 25 mg/m<sup>2</sup> up to a maximum dose of 150 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>Neutropenia</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1 (1,500 to 1,999/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 (1,000 to 1,499/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (500 to 999/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4 (&lt;500/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Neutropenic fever</b> (grade 4 neutropenia and ≥ grade 2 fever)</p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Manage promptly with antibiotic support.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Other hematologic toxicities</b></p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Dose modifications for leukopenia, thrombocytopenia, and anemia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>Diarrhea</b></p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;">Patients with diarrhea should be carefully monitored and treated promptly; may require fluid and electrolyte therapy. Avoid diuretics and laxatives in patients experiencing diarrhea. Advise patients to have loperamide readily available for the treatment of late diarrhea. Delay weekly irinotecan until bowel function has returned to baseline for at least 24 hours (without antidiarrheals).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1 (2 to 3 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 (4 to 6 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (7 to 9 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4 (≥10 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>Other nonhematologic toxicities<sup>b</sup></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypersensitivity reaction (anaphylactic reaction)</p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Discontinue irinotecan if anaphylactic reaction occurs.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Pulmonary toxicity</p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Interrupt chemotherapy and evaluate for progressive changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms (eg, dyspnea, cough, fever). Discontinue all chemotherapy and manage as clinically indicated if interstitial pulmonary disease is diagnosed.</p></td></tr></tbody></table>
<table border="1" data-table-id="campcomb" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colorectal Cancer: Combination Schedules: Recommended Dosage Modifications<sup>a</sup></b></caption>
<colgroup><col/>
<col/>
<col/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Toxicity grade (value)</p></th>
<th align="center">
<p style="text-indent:0em;">During a cycle of therapy</p></th>
<th align="center">
<p style="text-indent:0em;">At the start of subsequent cycles of therapy (after adequate recovery), compared to the starting dose in the previous cycle<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3" valign="top">
<p style="text-indent:0em;">
<sup>a </sup>All dose modifications should be based on the worst preceding toxicity.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="top">
<p style="text-indent:0em;">
<sup>b </sup>Excludes alopecia, anorexia, asthenia.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">No toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Neutropenia</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1 (1,500 to 1,999/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 (1,000 to 1,499/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 1 dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (500 to 999/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 1 dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4 (&lt;500/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 2 dose levels</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Neutropenic fever</b> (grade 4 neutropenia and ≥ grade 2 fever)</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Manage promptly with antibiotic support.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">Omit dose until resolved, then ↓ 2 dose levels</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Other hematologic toxicities</b></p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Dose modifications for leukopenia or thrombocytopenia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Diarrhea</b></p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;">Patients with diarrhea should be carefully monitored and treated promptly; may require fluid and electrolyte therapy. Avoid diuretics and laxatives in patients experiencing diarrhea. Advise patients to have loperamide readily available for the treatment of late diarrhea. Delay weekly irinotecan until bowel function has returned to baseline for at least 24 hours (without antidiarrheals).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1 (2 to 3 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Delay dose until resolved to baseline, then give same dose</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 (4 to 6 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to baseline, then ↓ 1 dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (7 to 9 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to baseline, then ↓ by 1 dose level</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 1 dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4 (≥10 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to baseline, then ↓ 2 dose levels</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 2 dose levels</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Other nonhematologic toxicities<sup>b</sup></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 1, then ↓ 1 dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 1 dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 2 dose levels</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypersensitivity reaction (anaphylactic reaction)</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Discontinue irinotecan if anaphylactic reaction occurs.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Mucositis and/or stomatitis</p></td>
<td align="center">
<p style="text-indent:0em;">Decrease only fluorouracil, not irinotecan</p></td>
<td align="center">
<p style="text-indent:0em;">Decrease only fluorouracil, not irinotecan</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Pulmonary toxicity</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Interrupt chemotherapy and evaluate for progressive changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms (eg, dyspnea, cough, fever). Discontinue all chemotherapy and manage as clinically indicated if interstitial pulmonary disease is diagnosed.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F184461"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;">Weekly dosing schedule: No dosing adjustment is recommended</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;">Every 3-week dosing colorectal cancer schedule: Recommended initial dose is 300 mg/m<sup>2</sup>/dose for patients ≥70 years</p></div>
<div class="block dop drugH1Div" id="F10819706"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13238" href="/d/html/13238.html" rel="external">see "Irinotecan (conventional): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A reduction in the starting dose by at least one dose level should be considered for prior pelvic/abdominal radiotherapy, performance status of ≥2, or known homozygosity for UGT1A1*28 allele. Consider prophylaxis with oral third generation cephalosporins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21509928','lexi-content-ref-20405511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21509928','lexi-content-ref-20405511'])">Ref</a></span>), and/or atropine IV or SubQ for treatment in patients with cholinergic symptoms (eg, increased salivation, diaphoresis, abdominal cramping) or diarrhea. Irinotecan is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>). Details concerning dosage in combination regimens should also be consulted. Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d6fa58e-f3ba-4910-be9e-30b6a819439c">Neuroblastoma, refractory or palliative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Neuroblastoma, refractory or palliative:</b> Limited data available<b>: </b>Children ≥2 years and Adolescents: IV: 50 mg/m<sup>2</sup> over 1 hour once daily on days 1 to 5 (5 doses), in combination with temozolomide; repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15637685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15637685'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4befdb03-7770-481a-a5f4-6ccfb3550030">Solid tumor or CNS tumor; refractory or relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Solid tumor or CNS tumor; refractory or relapsed (low-dose, protracted schedule):</b> Limited data available: Children ≥2 years and Adolescents: IV: 15 mg/m<sup>2</sup> over 1 hour once daily on days 1 to 5 (5 doses) and days 8 to 12 (5 doses) of a 28-day treatment cycle; in the trial, a maximum dose of 30 mg/dose was reported; may repeat cycle if tolerated in combination with temozolomide and vincristine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20405511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20405511'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Solid tumor or CNS tumor; refractory or relapsed:</b> Limited data available: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Daily regimen:</p>
<p style="text-indent:-2em;margin-left:8em;">IV: Children ≥2 years and Adolescents: 50 mg/m<sup>2</sup> over 1 hour once daily on days 1 to 5 (5 doses) as a single agent; repeat cycle every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15637685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15637685'])">Ref</a></span>); some protocols include combination with temozolomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23703550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23703550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Children and Adolescents: 90 mg/m<sup>2 </sup>once daily on days 1 to 5 (5 doses) repeat every 3 weeks; in combination with vincristine and temozolomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20049936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20049936'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Weekly regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15768380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15768380'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">Heavily pretreated patients (eg, ≥2 prior chemotherapy regimens): IV: 125 mg/m<sup>2</sup>/dose once weekly for 4 weeks over 90 minutes, repeat cycle every 6 weeks</p>
<p style="text-indent:-2em;margin-left:10em;">Less-heavily pretreated patients (≤2 prior chemotherapy regimens): IV: 160 mg/m<sup>2</sup>/dose once weekly for 4 weeks over 90 minutes, repeat cycle every 6 weeks</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ee0296b-1039-4b5d-9729-39bab2271fd7">Rhabdomyosarcoma, refractory or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Rhabdomyosarcoma, refractory or metastatic:</b> Limited data available: Children and Adolescents: IV: 50 mg/m<sup>2</sup> once daily for 5 days (maximum dose: 100 mg/dose) on protocol specific weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20837952','lexi-content-ref-26503200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20837952','lexi-content-ref-26503200'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available. See tables for adult dosage recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">It is recommended that new courses begin only after the granulocyte count recovers to ≥1,500/mm<sup>3</sup>, the platelet counts recover to ≥100,000/mm<sup>3</sup>, and treatment-related diarrhea has fully resolved. Depending on the patient's ability to tolerate therapy, adult doses should be adjusted in increments of 25 to 50 mg/m<sup>2</sup>. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consider discontinuing irinotecan. See tables for adult dosage recommendations.</p>
<table border="1" data-table-id="campsing" frame="border" rules="all">
<caption style="text-align:center;">
<b>Colorectal Cancer: Single-Agent Schedule: Recommended <span style="text-decoration: underline">Adult</span> Dosage Modifications<sup>A</sup></b></caption>
<colgroup><col/>
<col/>
<col/>
<col/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Toxicity NCI Grade<sup>B </sup> (Value)</p></th>
<th align="center">
<p style="text-indent:0em;">During a Cycle of Therapy</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">At Start of Subsequent Cycles of Therapy (After Adequate Recovery), Compared to Starting Dose in Previous Cycle<sup>A</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Weekly</p></th>
<th align="center">
<p style="text-indent:0em;">Weekly</p></th>
<th align="center">
<p style="text-indent:0em;">Once Every 3 Weeks</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>A</sup>All dose modifications should be based on the worst preceding toxicity.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>B</sup>National Cancer Institute Common Toxicity Criteria (version 1.0).</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>C</sup>Excludes alopecia, anorexia, asthenia.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">No toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">↑ 25 mg/m<sup>2</sup> up to a maximum dose of 150 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>Neutropenia</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 (1,500 to 1,999/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 (1,000 to 1,499/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 (500 to 999/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4 (&lt;500/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Neutropenic Fever</b> (grade 4 neutropenia and ≥ grade 2 fever)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Other Hematologic Toxicities</b></p></td>
<td align="center" colspan="3">
<p style="text-indent:0em;">Dose modifications for leukopenia, thrombocytopenia, and anemia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>Diarrhea</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 (2-3 stools/day &gt;pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 (4-6 stools/day &gt;pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 (7-9 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4 (≥10 stools/day &gt; pretreatment)</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<b>Other Nonhematologic Toxicities<sup>C </sup></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td>
<td align="center">
<p style="text-indent:0em;">Maintain dose level</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 25 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">↓ 50 mg/m<sup>2</sup></p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F51159601"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no pediatric specific dosage adjustments; refer to individual protocols; use with caution. Dialysis: Based on experience in adult patients, avoiding use or dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51159602"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no pediatric specific dosage adjustments; refer to individual protocols. Based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block adr drugH1Div" id="F184424"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency of adverse reactions reported for single-agent use of irinotecan only. In limited pediatric experience, dehydration (often associated with severe hypokalemia and hyponatremia) was among the most significant grade 3/4 adverse events, with a frequency up to 29%. In addition, grade 3/4 infection was reported in 24%.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasodilation (9% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Cholinergic syndrome (47%; includes diaphoresis, flushing, increased peristalsis, lacrimation, miosis, rhinitis, sialorrhea), pain (23% to 24%), dizziness (15% to 21%), insomnia (19%), headache (17%), chills (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (46% to 72%), diaphoresis (16%), skin rash (13% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (30%), dehydration (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (late: 83% to 88%, grades 3/4: 14% to 31%; early: 43% to 51%, grades 3/4: 7% to 22%), nausea (70% to 86%), abdominal pain (57% to 68%), vomiting (62% to 67%), abdominal cramps (57%), anorexia (44% to 55%), constipation (30% to 32%), mucositis (30%), flatulence (12%), stomatitis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (60% to 97%; grades 3/4: 5% to 7%), leukopenia (63% to 96%, grades 3/4: 14% to 28%), thrombocytopenia (96%, grades 3/4: 1% to 4%), neutropenia (30% to 96%; grades 3/4: 14% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (84%), increased serum alkaline phosphatase (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (69% to 76%), back pain (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (22%), cough (17% to 20%), rhinitis (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (44% to 45%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (10%), hypotension (6%), thromboembolism (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Drowsiness (9%), confusion (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (10%), dyspepsia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (grades 3/4: 2% to 6%), hemorrhage (grades 3/4: 1% to 5%), neutropenic infection (grades 3/4: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum AST (10%), ascites (grades 3/4: ≤9%), jaundice (grades 3/4: ≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anaphylactoid reaction, anaphylaxis, angina pectoris, arterial thrombosis, bradycardia, cardiac arrhythmia, cerebral infarction, cerebrovascular accident, circulatory shock, colitis, deep vein thrombophlebitis, dysarthria, embolism, gastrointestinal hemorrhage, gastrointestinal obstruction, hepatomegaly, hiccups, hyperglycemia, hypersensitivity reaction, hyponatremia, immune thrombocytopenia, increased amylase, increased serum ALT, increased serum lipase, interstitial pulmonary disease, intestinal obstruction, intestinal perforation, ischemic colitis, ischemic heart disease, lymphocytopenia, megacolon, muscle cramps, myocardial infarction, pancreatitis, paresthesia, peripheral vascular disease, pulmonary embolism; pulmonary toxicity (includes dyspnea, fever, reticulonodular infiltrates on chest x-ray), renal insufficiency, syncope, thrombophlebitis, thrombosis, typhlitis (including neutropenic typhlitis), ulcer, ulcerative colitis, vertigo</p></div>
<div class="block coi drugH1Div" id="F184438"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to irinotecan or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Coadministration with azole antifungals (ketoconazole, fluconazole, itraconazole); patients with hereditary fructose intolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F184421"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Irinotecan may cause severe myelosuppression. Deaths due to sepsis following severe neutropenia have been reported. Complications due to neutropenia should be promptly managed with antibiotics. Patients who have previously received pelvic/abdominal radiation therapy have an increased risk of severe bone marrow suppression; the incidence of grade 3 or 4 neutropenia was higher in patients receiving weekly irinotecan who have previously received pelvic/abdominal radiation therapy. Concurrent radiation therapy is not recommended with irinotecan (based on limited data).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: Severe diarrhea may be dose-limiting and potentially fatal; early-onset and late-onset diarrhea may occur. Early diarrhea occurs during or within 24 hours of receiving irinotecan and is characterized by cholinergic symptoms; may be prevented or treated with atropine. Late diarrhea may be life-threatening and should be promptly treated with loperamide. Antibiotics may be necessary if patient develops ileus, fever, or severe neutropenia. Early diarrhea is generally transient and rarely severe; cholinergic symptoms may include increased salivation, rhinitis, miosis, diaphoresis, flushing, abdominal cramping, and lacrimation; bradycardia may also occur. Cholinergic symptoms may occur more frequently with higher irinotecan doses. Late diarrhea occurs more than 24 hours after treatment, which may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea may be complicated by colitis, ulceration, bleeding, ileus, obstruction, or infection; cases of megacolon and intestinal perforation have been reported. The median time to onset for late diarrhea is 5 days with every-3-week irinotecan dosing and 11 days with weekly dosing. Advise patients to have loperamide readily available for the treatment of late diarrhea.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Irinotecan is an irritant. Avoid extravasation; if extravasation occurs, the manufacturer recommends flushing the external site with sterile water and applying ice.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions (including anaphylaxis) have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Fatal cases of interstitial pulmonary disease–like events have been reported with single-agent and combination therapy. Risk factors for pulmonary toxicity include preexisting lung disease, use of pulmonary toxic medications, radiation therapy, and colony-stimulating factors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Renal impairment and acute renal failure have been reported, possibly due to dehydration secondary to diarrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bowel obstruction: Patients with bowel obstruction should not be treated with irinotecan until resolution of obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Exposure to the active metabolite (SN-38) is increased in hepatic impairment; toxicities may be increased. Patients with even modest elevations in total serum bilirubin levels (1 to 2 mg/dL) have a significantly greater likelihood of experiencing first-course grade 3 or 4 neutropenia than those with bilirubin levels that were &lt;1 mg/dL. Patients with abnormal glucuronidation of bilirubin, such as those with Gilbert syndrome, may also be at greater risk of myelosuppression when receiving therapy with irinotecan.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-drug interactions: CYP3A4 enzyme inducers may decrease exposure to irinotecan and SN-38 (active metabolite); enzyme inhibitors may increase exposure. For use in patients with CNS tumors (off-label use), selection of antiseizure medications that are not enzyme inducers is preferred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients &gt;65 years of age are at greater risk for early and late diarrhea. A dose reduction is recommended for patients ≥70 years of age receiving the every-3-week regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pelvic/abdominal radiation recipients: Previously received pelvic/abdominal radiation may increase risk of severe myelosuppression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Performance status: Higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle discontinuation, and early mortality were observed in patients with a performance status of 2 than in patients with a performance status of 0 or 1.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reduced UGT1A1 activity: Patients homozygous for either the UGT1A1*28 or *6 alleles (*28/*28, *6/*6) or who are compound or double heterozygous for the UGT1A1*28 and *6 alleles (*6/*28) are at increased risk of severe or life-threatening neutropenia with irinotecan due to poor metabolism of UGT1A1; UGT1A1-poor metabolizers have increased systemic exposure to SN-38 (active metabolite). Patients who are heterozygous for either the UGT1A1*28 or *6 alleles (*1/*28, *1/*6) are intermediate metabolizers and may also be at increased risk of severe or life-threatening neutropenia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Conventional vs liposomal formulation dosing: Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sorbitol: Product contains sorbitol; do not use in patients with hereditary fructose intolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Except as part of a clinical trial, use in combination with the fluorouracil and leucovorin administered for 4 or 5 consecutive days every 4 weeks (“Mayo Clinic” regimen) is not recommended due to increased toxicity.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878502"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric patients, provide antibiotic support if patient develops persistent diarrhea (grade 3 or 4), ileus, fever, sepsis, or severe neutropenia; cefixime (8 mg/kg/day, maximum dose: 400 mg) has been used in children as prophylaxis for diarrhea beginning 5 days prior to irinotecan therapy and continued throughout course (Wagner 2008); cefpodoxime (10 mg/kg/day divided twice daily, maximum dose: 200 mg) has also been used (McNall-Knapp 2010; Wagner 2010).</p></div>
<div class="block foc drugH1Div" id="F184432"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/2 mL (2 mL); 100 mg/5 mL (5 mL); 300 mg/15 mL (15 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Camptosar: 40 mg/2 mL (2 mL); 100 mg/5 mL (5 mL); 300 mg/15 mL (15 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/2 mL (2 mL); 100 mg/5 mL (5 mL); 300 mg/15 mL (15 mL); 500 mg/25 mL (25 mL)</p></div>
<div class="block geq drugH1Div" id="F184417"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323228"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Camptosar Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/2 mL (per mL): $16.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $9.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/15 mL (per mL): $9.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Irinotecan HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/2 mL (per mL): $5.40 - $138.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $4.32 - $138.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/15 mL (per mL): $8.00 - $8.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/25 mL (per mL): $7.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867256"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Camptosar: 20 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (2 mL, 5 mL, 25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL)</p></div>
<div class="block adm drugH1Div" id="F184435"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by IV infusion, usually over 90 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Premedications: Irinotecan is associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); premedication with dexamethasone and a 5-HT<sub>3</sub> blocker is recommended 30 minutes prior to administration; prochlorperazine may be considered for subsequent use (if needed). Consider atropine 0.25 to 1 mg IV or SubQ as premedication for or treatment of cholinergic symptoms (eg, increased salivation, rhinitis, miosis, diaphoresis, abdominal cramping) or early onset diarrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">Diarrhea management: Advise patients to have loperamide readily available for management of late diarrhea. The recommended regimen to manage late diarrhea is loperamide 4 mg orally at onset of late diarrhea, followed by 2 mg every 2 hours (or 4 mg every 4 hours at night) until 12 hours have passed without a bowel movement. If diarrhea recurs, then repeat loperamide administration. Loperamide should not be used for more than 48 consecutive hours.</p></div>
<div class="block admp drugH1Div" id="F52613084"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV infusion: Infuse usually over 90 minutes; some pediatric protocols infuse the dose over 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15637685','lexi-content-ref-20405511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15637685','lexi-content-ref-20405511'])">Ref</a></span>); consult specific protocol. Higher incidence of cholinergic symptoms (increased salivation, rhinitis, miosis, diaphoresis, abdominal cramping) have been reported with more rapid infusion rates; consider prophylaxis with oral cephalosporin antibiotics or rescue atropine for acute-onset diarrhea.</p></div>
<div class="block hazard drugH1Div" id="F49132622"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F184433"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Colorectal cancer, metastatic:</b> Treatment of metastatic carcinoma of the colon or rectum, either as first-line therapy (in combination with fluorouracil and leucovorin), or for recurrent or progressive disease following initial fluorouracil-based treatment.</p></div>
<div class="block off-label drugH1Div" id="F25474591"><span class="drugH1">Use: Off-Label: Adult</span><p>Cervical cancer, recurrent or metastatic; CNS tumor, recurrent glioblastoma; Esophageal cancer, metastatic or locally advanced; Ewing sarcoma, recurrent or progressive; Gastric cancer, metastatic or locally advanced; Non–small cell lung cancer, advanced; Ovarian cancer, recurrent; Pancreatic cancer, advanced or metastatic; Pancreatic cancer, potentially curable, adjuvant therapy; Rhabdomyosarcoma, metastatic or relapsed/progressive; Small bowel adenocarcinoma, advanced unresectable or metastatic; Small cell lung cancer, extensive stage; Small cell lung cancer, limited stage; Unknown primary adenocarcinoma</p></div>
<div class="block mst drugH1Div" id="F3401643"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Conventional formulation (Camptosar) may be confused with the liposomal formulation (Onivyde)</p>
<p style="text-indent:-2em;margin-left:4em;">Irinotecan (conventional) may be confused with irinotecan (liposomal), sacituzumab govitecan, topotecan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F184487"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor), UGT1A1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F184426"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Irinotecan Products may enhance the nephrotoxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products. Management: Avoid administration of strong CYP3A4 inducers during irinotecan treatment, and substitute non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. Management: Avoid administration of strong CYP3A4 inhibitors during and within 1 week prior to irinotecan administration, unless no therapeutic alternatives to these agents exist. If combined, monitor closely for increased irinotecan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: Irinotecan Products may enhance the adverse/toxic effect of Sacituzumab Govitecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. St John's Wort may decrease the serum concentration of Irinotecan Products. Management: Avoid administration of St John's wort during irinotecan treatment, and consider substituting non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telotristat Ethyl: May decrease serum concentrations of the active metabolite(s) of Irinotecan Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease serum concentrations of the active metabolite(s) of Irinotecan Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A1 Inhibitors: May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307960"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use highly effective contraception during therapy and for 6 months after the last irinotecan dose. Patients with partners who could become pregnant should use condoms during therapy and for 3 months after the last dose of irinotecan.</p>
<p style="text-indent:0em;margin-top:2em;">Menstrual cycle changes and impairment of female fertility may occur with irinotecan therapy.</p></div>
<div class="block pri drugH1Div" id="F184440"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to irinotecan may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of irinotecan (conventional) during pregnancy are limited (Abellar 2009; Cirillo 2012; Kozai 2022; Taylor 2009).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach. In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F3197632"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan and its metabolites are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy and for 7 days after the last irinotecan dose.</p></div>
<div class="block dic drugH1Div" id="F3342893"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Contains sorbitol; do not use in patients with hereditary fructose intolerance.</p></div>
<div class="block mop drugH1Div" id="F184430"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential, platelet count, and hemoglobin with each dose; bilirubin, electrolytes (with severe diarrhea). Verify pregnancy status prior to use (in patients who could become pregnant). Monitor for cholinergic reactions; monitor bowel movements and hydration status. Monitor for signs/symptoms of pulmonary toxicity (particularly in patients with risk factors such as preexisting lung disease, use of pulmonary toxicity medications, radiation therapy, and colony-stimulating factors); promptly evaluate progressive changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms (eg, dyspnea, cough, fever). Monitor for hypersensitivity reactions; monitor infusion site for signs of inflammation.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider UGT1A1 genotype testing for the *28 and *6 alleles to determine UGT1A1 metabolizer status; closely monitor for neutropenia during and after treatment with irinotecan.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F184420"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Irinotecan and its active metabolite (SN-38) bind reversibly to topoisomerase I-DNA complex preventing religation of the cleaved DNA strand. This results in the accumulation of cleavable complexes and double-strand DNA breaks. As mammalian cells cannot efficiently repair these breaks, cell death consistent with S-phase cell cycle specificity occurs, leading to termination of cellular replication.</p></div>
<div class="block phk drugH1Div" id="F184437"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: ~37 L/m<sup>2</sup> (range: 15.2 to 77 L/m<sup>2</sup>) (Ma 2000); distributes to pleural fluid, sweat, and saliva</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 33 to 150 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: Predominantly albumin; Irinotecan: 30% to 68%, SN-38 (active metabolite): ~95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic to SN-38 (active metabolite) by carboxylesterase enzymes; may also undergo CYP3A4-mediated oxidative metabolism to several inactive metabolites (one of which may be hydrolyzed to release SN-38). SN-38 undergoes conjugation by UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. SN-38 AUC is increased in patients who are homozygous for either the UGT1A1*28 or *6 alleles, or who are compound heterozygous for these alleles.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Median: 9%; increased in presence of gefitinib (median: 42%) (Furman 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents (Ma 2000): Irinotecan: 2.66 hours (range: 1.82 to 4.47 hours); SN-38 (active metabolite): 1.58 hours (range: 0.29 to 8.28 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Irinotecan: 6 to 12 hours; SN-38: ~10 to 20 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Irinotecan: Oral: Children and Adolescents: 3 hours (Wagner 2010a)</p>
<p style="text-indent:-2em;margin-left:4em;">SN-38: Following 90-minute infusion: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: Irinotecan (11% to 20%), metabolites (SN-38 &lt;1%, SN-38 glucuronide, 3%)</p></div>
<div class="block phksp drugH1Div" id="F51193253"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance of irinotecan is decreased and exposure to the active metabolite (SN-38) is increased proportional to the degree of hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F184441"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Irinogen | Irinotecan | Irinotecan gp pharm | Irinotecan ima | Itoxaril | Kebirtecan | Satigene | Tiagrel | Trinotecan | Winol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinoliquid | Irinotecan accord | Irinotecan actavis | Irinotecan arcana | Irinotecan ebewe | Irinotecan fresenius | Irinotecan hikma | Irinotecan hospira | Irinotecan kabi | Irinotecan stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Irinoccord | Irinotecan | Irinotecan accord | Irinotecan actavis | Irinotecan ga | Irinotecan kabi | Irinotecan myx | Meditab irinotecan | Omegapharm Irinotecan | Tecan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Irinox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinosin | Irinotecan accord | Irinotecan actavis | Irinotecan EG | Irinotecan hospira | Irinotecan kabi | Irinotecan Mylan | Irinotecan Sandoz | Irinotecan vianex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Irinotecan accord | Irinotecan bulgerm | Irinotecan hospira | Irinotecan Hydrochloride Cipla | Irinotecan novamed</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Camptrix | Cloridrato de irinotecano | Cloritecan | Dosatecan | Evoterin | Irimac | Irnocam | Proto Itecan | Tecnotecan | Tevairinot | Zotecan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan actavis | Irinotecan ebewe | Irinotecan fresenius | Irinotecan Labatec | Irinotecan Orion | Irinotecan Sandoz | Irinotecan Teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Irinotecan | Itoxaril | Linatecan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai li | Campto</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blastovin | Camptosar | Irinkan | Irinocyt | Irinoseven | Irinotecan | Irinotel | Itoxaril | Labdosa fixano | Linatecan | Oncotan | Rotecan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinocol | Irinotecan accord | Irinotecan actavis | Irinotecan ebewe | Irinotecan fresenius | Irinotecan kabi | Irinotecan medac | Irinotecan Mylan | Irinotecan stada | Irinotecan Teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Axinotecan | Bw irican | Campto | Irino | Irinomedac | Irinotecan accord | Irinotecan actavis | Irinotecan amneal | Irinotecan aurobindo | Irinotecan awd | Irinotecan Cell Pharm | Irinotecan ever pharma | Irinotecan haemato | Irinotecan Hameln | Irinotecan hcl aqvida | Irinotecan hcl liv pharma | Irinotecan Hcl Omnicare | Irinotecan hcl ratiopharm | Irinotecan heumann | Irinotecan Hexal | Irinotecan hospira | Irinotecan kabi | Irinotecan Medicopharm | Irinotecan Oncotrade | Irinotecan Onkovis | Irinotecan Ratiopharm | Irinotecan tillomed | Irinotecan vipharm | Irinotecan Zyo | Irinotesin | Riboirino</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Hidrotecan | Irinotecan libra | Irinotel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Irinogen | Irinotecan | Irinotecan Sandoz | Itoxaril | Linatecan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan fresenius | Irinotecan hospira | Irinotecan kabi | Irinotecan Mayne</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan actavis | Irinotecan Gp-Pharm | Irinotecan Juste | Irinotecan Mylan | Irinotecan rovi | Irinotecan Sandoz | Irinotecan stada | Irinotecan Teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Irinotecan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan actavis | Irinotecan Bmm Pharma | Irinotecan ebewe | Irinotecan fresenius kabi | Irinotecan Mayne | Irinotecan medac | Irinotecan Mylan | Irinotecan Teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan actavis | Irinotecan Ebewe pharma France | Irinotecan hikma | Irinotecan hospira | Irinotecan kabi | Irinotecan medac | Irinotecan Mylan | Irinotecan Teva Sante</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan accord | Irinotecan medac</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Biotecan | Campto | Irican | Irinocan/demo | Irinotecan accord | Irinotecan medac | Irinotecan Teva | Irinotecan/Generics | Irinotecan/medicus | Mizantrone | Santacil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan Teva | Irinotesin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan kabi | Irinotesin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan actavis | Irinotecan ebewe | Irinotecan hikma | Irinotecan hms pharma | Irinotecan Medico Uno | Irinotecan Mylan | Irinotecan Polpharma | Irinotecan Ratiopharm | Irinotecan Teva | Tekazol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actatecan | Campto | Irinotecan | Iritero | Irnocam | Kabitec | Romisan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Campto | Imtus | Irinomil | Irinopar | Irinot | Irinotel | Irinotraz | Iritero | Irnocam | Irnocel | Irnozen | Lilrincan | ReliTecan | Rinotec | Stritosar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan accord | Irinotecan kabi | Irinotecan M.G. | Irinotecan Sandoz | Irinotecan Tev</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan HCL | Irinotecan hydrochloride sandoz | Irinotecan hydrochloride taiho | Topotecin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinogen | Irinotel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung irinotecan hcl | Calmtop | Campto | Camtecan | Camtotecan | Crabcan | Dongsung irinotecan hydrochloride | Ildong irinotecan | Inocan | Inotecan | Irinotecan HCL | Irinotecan HCL Boryung | Irinotel | Iritecan | Iritecin | Pfizer irinotecan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan gp pharm</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan accord | Irinotecan actavis | Irinotecan alvogen | Irinotecan hospira | Irinotecan kabi | Irinotecan Mayne | Irinotecan seacross | Irinotecan Teva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan ebewe | Irinotecan kabi | Irinotecan Mayne</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Asinib | Badix | Camptocrin | Camptosar | Colizactive | Daritex a | Etoniri | Feradech | Iraplax | Irinkan | Irinotecan | Junostal | Zurisar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Seacross irinotecan hydrochloride | Tekamen</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irnocel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotecan actavis | Irinotecan hcl 3 water mylan | Irinotecan hcl 3 water pch | Irinotecan hcl cf | Irinotecan hcl trihydraat fresenius kabi | Irinotecan hcl trihydraat hospira | Irinotecan hcl trihydraat ratiopharm | Irinotecan hcl trihydraat sandoz | Irinotecan hydrochloride trihydraat accord</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinokabi | Irinotecan accord | Irinotecan actavis | Irinotecan Bmm Pharma | Irinotecan fresenius kabi | Irinotecan hospira | Irinotecan Mayne</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Irinotecan | Irinotecan accord | Irinotecan Rex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Irinotecan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biomedis irinotecan | Campto | Irican | Irino | Irinotesin | Iritero | Pfizer irinotecan | Topoblock</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinocan | Irinotecan medac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan ebewe | Irinotecan fresenius | Irinotecan kabi | Irinotecan medac | Irinotecan Polpharma | Irinotesin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Camptosar | Irinotecan HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Campto | Faultenocan | Irinotecano | Irinotecano accord | Irinotecano Basi | Irinotecano hikma</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Efixano | Irinogen | Irinotecan fada | Irinotecan fusa | Irinotecan lasca | Irinotecan libra | Irinotecan nl pharma | Irinotecan tuteur | Itoxaril | Kebirtecan | Linatecan | Trinotecan | Trinotecan filaxis</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Campto</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan alvogen | Irinotecan ebewe | Irinotecan kabi | Irinotecan medac | Irinotecan stada | Irinotesin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Camptera | Campto | Campto cs | Irinotecan | Irinotecan filaxis | Irinotecan j | Irinotecan medac | Irinotecan Pliva-lachema | Irinotecan Teva | Irinotel | Iriten | Iritero | Irnocam</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan | Irinotel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan actavis | Irinotecan ebewe | Irinotecan fresenius kabi | Irinotecan hospira | Irinotecan Teva | Irinotecan vianex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan dbl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotekan Actavis | Irinotekan ebewe | Irinotekanijev klorid mylan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan accord | Irinotecan ebewe | Irinotecan HCL Actavis | Irinotecan hikma | Irinotecan kabi | Irinotecan medac | Irinotecan stada | Irinotecan Teva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Campto | DBL Irinotecan | Irinotel | Irinotesin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinotecan kabi | Irinotecan Mylan | Irinotesin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Campto | Irinocam | Tekamen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Campto conc | Herocan conc | Irenax | Irino | Irinotecan | Irinotel</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Camptera | Campto | Camptomeda | Irinosindan | Irinotecan | Irinotecan accord | Irinoval | Irinovista | Iritero | Irnocam</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Efixano | Irinotecan | Irinotecan clorhidrato trihidrato Servycal | Itoxaril | Trinotecan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Elinatecan | Irinotecan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Irinotecan | Campto | Cipla Irinotecan | Irinotas | Irinotecan safeline | Iritero | Sandoz irinotecan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Irinotel</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Imtus | Irinotel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462010">
<a name="18462010"></a>Abellar RG, Pepperell JR, Greco D, et al. Effects of chemotherapy during pregnancy on the placenta. <i>Pediatr Dev Pathol</i>. 2009;12(1):35-41. doi:10.2350/08-03-0435.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/18462010/pubmed" id="18462010" target="_blank">18462010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11857295">
<a name="11857295"></a>Ajani JA, Baker J, Pisters PW, et al, “CPT-11 Plus Cisplatin in Patients With Advanced, Untreated Gastric or Gastroesophageal Junction Carcinoma: Results of a Phase II Study,” <i>Cancer</i>, 2002, 94(3):641-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/11857295/pubmed" id="11857295" target="_blank">11857295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115869">
<a name="21115869"></a>Bagatell R, London WB, Wagner LM, et al, "Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study," <i>J Clin Oncol</i>, 2011, 29(2):208-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21115869/pubmed" id="21115869" target="_blank">21115869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2016;34(22):2654-2668. doi: 10.1200/JCO.2016.67.5561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15768380">
<a name="15768380"></a>Bomgaars L, Kerr J, Berg S, et al, "A Phase I Study of Irinotecan Administered on a Weekly Schedule in Pediatric Patients," <i>Pediatr Blood Cancer</i>, 2006, 46(1):50-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/15768380/pubmed" id="15768380" target="_blank">15768380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17925558">
<a name="17925558"></a>Bomgaars LR, Bernstein M, Krailo M, et al, "Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study," <i>J Clin Oncol</i>, 2007, 25(29):4622-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17925558/pubmed" id="17925558" target="_blank">17925558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15514373">
<a name="15514373"></a>Bouché O, Raoul JL, Bonnetain F, et al, “Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803,” <i>J Clin Oncol</i>, 2004, 22(21):4319-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/15514373/pubmed" id="15514373" target="_blank">15514373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Camptosar.1">
<a name="Camptosar.1"></a>Camptosar (irinotecan) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CamptosarCan.1">
<a name="CamptosarCan.1"></a>Camptostar (irinotecan) [product monograph] Kirkland, Quebec, Canada: Pfizer Canada ULC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19637327">
<a name="19637327"></a>Casey DA, Wexler LH, Merchant MS, et al, “Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,” <i>Pediatr Blood Cancer</i>, 2009, 53(6):1029-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19637327/pubmed" id="19637327" target="_blank">19637327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19204194">
<a name="19204194"></a>Chen G, Huynh M, Fehrenbacher L, et al, “Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 2009, 27(9):1401-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19204194/pubmed" id="19204194" target="_blank">19204194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37337890">
<a name="37337890"></a>Chui CY, Moes DJAR, Koolen SLW, Swen JJ, Gelderblom H. Pharmacokinetic profile of irinotecan in patients with chronic kidney disease: two cases and literature review. <i>Br J Clin Pharmacol</i>. 2023;89(9):2920-2925. doi:10.1111/bcp.15833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/37337890/pubmed" id="37337890" target="_blank">37337890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23389374">
<a name="23389374"></a>Cirillo M, Musola M, Cassandrini PA, Lunardi G, Venturini M. Irinotecan during pregnancy in metastatic colon cancer. <i>Tumori</i>. 2012;98(6):155e-157e.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/23389374/pubmed" id="23389374" target="_blank">23389374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21561347">
<a name="21561347"></a>Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <i>N Engl J Med</i>. 2011;364(19):1817-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21561347/pubmed" id="21561347" target="_blank">21561347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575490">
<a name="30575490"></a>Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. <i>N Engl J Med</i>. 2018;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/30575490/pubmed" id="30575490" target="_blank">30575490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15718320">
<a name="15718320"></a>Conroy T, Paillot B, François E, et al, “Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer--A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study,” <i>J Clin Oncol</i>, 2005, 23(6):1228-1236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/15718320/pubmed" id="15718320" target="_blank">15718320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11990694">
<a name="11990694"></a>Cosetti M, Wexler LH, Calleja E, et al, “Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience,” <i>J Pediatr Hematol Oncol</i>, 2002, 24(2):101-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/11990694/pubmed" id="11990694" target="_blank">11990694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338525">
<a name="26338525"></a>Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncol</i>. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/26338525/pubmed" id="26338525" target="_blank">26338525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193575">
<a name="19193575"></a>Czock D, Rasche FM, Boesler B, Shipkova M, Keller F. Irinotecan in cancer patients with end-stage renal failure. <i>Ann Pharmacother</i>. 2009;43(2):363-369. doi:10.1345/aph.1L511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19193575/pubmed" id="19193575" target="_blank">19193575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18288083">
<a name="18288083"></a>de Jong FA, van der Bol JM, Mathijssen RH, et al. Renal function as a predictor of irinotecan-induced neutropenia. <i>Clin Pharmacol Ther</i>. 2008;84(2):254-262. doi:10.1038/sj.clpt.6100513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/18288083/pubmed" id="18288083" target="_blank">18288083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29520731">
<a name="29520731"></a>de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. <i>Clin Pharmacokinet</i>. 2018;57(10):1229-1254. doi:10.1007/s40262-018-0644-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/29520731/pubmed" id="29520731" target="_blank">29520731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470860">
<a name="17470860"></a>Falcone A, Ricci S, Brunetti I, et al, “Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,” <i>J Clin Oncol</i>, 2007, 25(13):1670-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17470860/pubmed" id="17470860" target="_blank">17470860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al, “Hepatotoxicity of Chemotherapy,” <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720927">
<a name="19720927"></a>Friedman HS, Prados MD, Wen PY, et al, “Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma,” <i>J Clin Oncol</i>, 2009, 27(28):4733-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19720927/pubmed" id="19720927" target="_blank">19720927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947725">
<a name="17947725"></a>Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. <i>J Clin Oncol</i>. 2007;25(30):4779-4786. doi:10.1200/JCO.2007.11.3357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17947725/pubmed" id="17947725" target="_blank">17947725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12610178">
<a name="12610178"></a>Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.<i> J Clin Oncol.</i> 2003;21(5):807-814. doi: 10.1200/JCO.2003.08.058.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/12610178/pubmed" id="12610178" target="_blank">12610178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26337772">
<a name="26337772"></a>Fujita K, Masuo Y, Okumura H, et al. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. <i>Pharm Res</i>. 2016;33(2):269-282. doi:10.1007/s11095-015-1785-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/26337772/pubmed" id="26337772" target="_blank">26337772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19687340">
<a name="19687340"></a>Furman WL, Navid F, Daw NC, et al, "Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors," <i>J Clin Oncol</i>, 2009, 27(27):4599-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19687340/pubmed" id="19687340" target="_blank">19687340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12712459">
<a name="12712459"></a>Gajjar A, Chintagumpala MM, Bowers DC, et al, “Effect of Intrapatient Dosage Escalation of Irinotecan on Its Pharmacokinetics in Pediatric Patients Who Have High-Grade Gliomas and Receive Enzyme-Inducing Anticonvulsant Therapy,” <i>Cancer</i>, 2003, 97(9 Suppl):2374-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/12712459/pubmed" id="12712459" target="_blank">12712459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25287828">
<a name="25287828"></a>Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. <i>J Clin Oncol</i>. 2014;32(31):3520-3526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/25287828/pubmed" id="25287828" target="_blank">25287828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20164695">
<a name="20164695"></a>Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. <i>Cancer J.</i> 2010;16(1):70-75. doi: 10.1097/PPO.0b013e3181c6aa89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20164695/pubmed" id="20164695" target="_blank">20164695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16648503">
<a name="16648503"></a>Hanna N, Bunn PA Jr, Langer C, et al, “Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 2006, 24(13):2038-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/16648503/pubmed" id="16648503" target="_blank">16648503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18779613">
<a name="18779613"></a>Hermes A, Bergman B, Bremnes R, et al, “Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial,” <i>J Clin Oncol</i>, 2008, 26(26):4261-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/18779613/pubmed" id="18779613" target="_blank">18779613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24190112">
<a name="24190112"></a>Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. <i>J Clin Oncol</i>. 2013; 31(35):4438-4444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/24190112/pubmed" id="24190112" target="_blank">24190112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12781433">
<a name="12781433"></a>Hirose T, Horichi, N, Ohmori T, et al, “Phase II Study of Irinotecan and Carboplatin in Patients With the Refractory or Relapsed Small Cell Lung Cancer,” <i>Lung Cancer</i>, 2003, 40(3):333-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/12781433/pubmed" id="12781433" target="_blank">12781433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21617725">
<a name="21617725"></a>Huang SH, Chao Y, Wu YY, et al. Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer. <i>Tumori</i>. 2011;97(2):243-247. doi:10.1177/030089161109700221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21617725/pubmed" id="21617725" target="_blank">21617725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10506629">
<a name="10506629"></a>Ilson DH, Saltz L, Enzinger P, et al, “Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer,” <i>J Clin Oncol</i>, 1999, 17(10):3270-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/10506629/pubmed" id="10506629" target="_blank">10506629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34703007">
<a name="34703007"></a>Karas S, Etheridge AS, Nickerson DA, et al. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. <i>Br J Cancer</i>. 2022;126(4):640-651. doi:10.1038/s41416-021-01589-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/34703007/pubmed" id="34703007" target="_blank">34703007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180816">
<a name="31180816"></a>Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. <i>J Clin Oncol.</i> 2019;37(23):2082-2088. doi: 10.1200/JCO.19.00946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/31180816/pubmed" id="31180816" target="_blank">31180816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35702554">
<a name="35702554"></a>Kozai L, Benavente K, Obeidat A, Acoba J. FOLFOXIRI in pregnant women with colorectal cancer: a case report and review of the literature. <i>Case Rep</i>
<i>Oncol</i>. 2022;15(1):447-454. doi:10.1159/000524325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/35702554/pubmed" id="35702554" target="_blank">35702554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24309370">
<a name="24309370"></a>Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. <i>Lancet Oncol.</i> 2014;15(1):106-113. doi: 10.1016/S1470-2045(13)70511-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/24309370/pubmed" id="24309370" target="_blank">24309370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15637685">
<a name="15637685"></a>Kushner BH, Kramer K, Modak S, et al, "Five-Day Courses of Irinotecan as Palliative Therapy for Patients With Neuroblastoma," <i>Cancer</i>, 2005, 103(4):858-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/15637685/pubmed" id="15637685" target="_blank">15637685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19104814">
<a name="19104814"></a>Leary A, Assersohn L, Cunningham D, et al, “A Phase II Trial Evaluating Capecitabine and Irinotecan as Second Line Treatment in Patients With Oesophago-Gastric Cancer Who Have Progressed On, or Within 3 Months of Platinum-Based Chemotherapy,” <i>Cancer Chemother Pharmacol</i>, 2009, 64(3):455-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19104814/pubmed" id="19104814" target="_blank">19104814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25337750">
<a name="25337750"></a>Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>N Engl J Med</i>. 2014;371(17):1609-1618. doi:10.1056/NEJMoa1403108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/25337750/pubmed" id="25337750" target="_blank">25337750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10741701">
<a name="10741701"></a>Ma MK, Zamboni WC, Radomski KM, et al, "Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children With Recurrent Solid Tumors After Protracted Low-Dose Irinotecan," <i>Clin Cancer Res</i>, 2000, 6(3):813-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/10741701/pubmed" id="10741701" target="_blank">10741701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15469406">
<a name="15469406"></a>Marsh S and McLeod HL, “Pharmacogenetics of Irinotecan Toxicity,” <i>Pharmacogenomics</i>, 2004, 5(7):835-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/15469406/pubmed" id="15469406" target="_blank">15469406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20837952">
<a name="20837952"></a>Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. <i>J Clin Oncol.</i> 2010;28(30):4658-4663. doi: 10.1200/JCO.2010.29.7390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20837952/pubmed" id="20837952" target="_blank">20837952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11489791">
<a name="11489791"></a>Mathijssen RH, van Alphen RJ, Verweij J, et al, “Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11),” <i>Clin Cancer Res</i>, 2001, 7(8):2182-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/11489791/pubmed" id="11489791" target="_blank">11489791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16298422">
<a name="16298422"></a>Matsumoto K, Katsumata N, Yamanaka Y, et al. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. <i>Gynecol Oncol</i>. 2006;100(2):412-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/16298422/pubmed" id="16298422" target="_blank">16298422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21509928">
<a name="21509928"></a>McGregor LM, Stewart CF, Crews KR, et al, "Dose Escalation of Intravenous Irinotecan Using Oral Cefpodoxime: A Phase I Study in Pediatric Patients With Refractory Solid Tumors," <i>Pediatr Blood Cancer</i>, 2012, 58(3):372-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21509928/pubmed" id="21509928" target="_blank">21509928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20405511">
<a name="20405511"></a>McNall-Knapp RY, Williams CN, Reeves EN, et al, "Extended Phase I Evaluation of Vincristine, Irinotecan, Temozolomide, and Antibiotic in Children With Refractory Solid Tumors," <i>Pediatr Blood Cancer</i>, 2010, 54(7):909-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20405511/pubmed" id="20405511" target="_blank">20405511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31609637">
<a name="31609637"></a>Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). <i>J Clin Oncol.</i> 2019;37(35):3401-3411. doi:10.1200/JCO.19.01340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/31609637/pubmed" id="31609637" target="_blank">31609637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19605504">
<a name="19605504"></a>Moehler M, Kanzler S, Geissler M, et al, “A Randomized Multicenter Phase II Study Comparing Capecitabine With Irinotecan or Cisplatin in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction,” <i>Ann Oncol</i>. 2010;21(1):71-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19605504/pubmed" id="19605504" target="_blank">19605504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23703550">
<a name="23703550"></a>Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. <i>J Pediatr Hematol Oncol</i>. 2013;35(5):337-347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/23703550/pubmed" id="23703550" target="_blank">23703550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11784874">
<a name="11784874"></a>Noda K, Nishiwaki Y, Kawahara M, et al, “Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Small-Cell Lung Cancer,” <i>N Engl J Med</i>, 2002, 346(2):85-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/11784874/pubmed" id="11784874" target="_blank">11784874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079694">
<a name="17079694"></a>Ohe Y, Ohashi Y, Kubota K, et al, “Randomized Phase III Study of Cisplatin Plus Irinotecan Versus Carboplatin Plus Paclitaxel, Cisplatin Plus Gemcitabine, and Cisplatin Plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan,” <i>Ann Oncol</i>, 2007, 18(2):317-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17079694/pubmed" id="17079694" target="_blank">17079694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17264331">
<a name="17264331"></a>Pappo AS, Lyden E, Breitfeld P, et al, "Two Consecutive Phase II Window trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group," <i>J Clin Oncol</i>, 2007, 25(4):362-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17264331/pubmed" id="17264331" target="_blank">17264331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15930889">
<a name="15930889"></a>Park SH, Choi EY, Bang SM, et al, “Salvage Chemotherapy With Irinotecan and Cisplatin in Patients With Metastatic Gastric Cancer Failing Both 5-Fluorouracil and Taxanes,” <i>Anticancer Drugs</i>, 2005, 16(6):621-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/15930889/pubmed" id="15930889" target="_blank">15930889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):S160-S170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921462">
<a name="20921462"></a>Peeters M, Price TJ, Cervantes A, et al. Randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>J Clin Oncol</i>. 2010;28(31):4706-4713. doi:10.1200/JCO.2009.27.6055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20921462/pubmed" id="20921462" target="_blank">20921462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18281264">
<a name="18281264"></a>Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. <i>Ann Oncol</i>. 2008;19(6):1141-1145. doi:10.1093/annonc/mdn020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/18281264/pubmed" id="18281264" target="_blank">18281264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17409981">
<a name="17409981"></a>Pillot GA, Read WL, Hennenfent KL, et al, “A Phase II Study of Irinotecan and Carboplatin in Advanced Non-Small Cell Lung Cancer With Pharmacogenomic Analysis: Final Report,” <i>J Thorac Oncol</i>, 2006, 1(9):972-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17409981/pubmed" id="17409981" target="_blank">17409981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12409328">
<a name="12409328"></a>Raymond E, Boige V, Faivre S, et al, “Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction,” <i>J Clin Oncol</i>, 2002, 20(21):4303-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/12409328/pubmed" id="12409328" target="_blank">12409328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8648367">
<a name="8648367"></a>Rothenberg ML, Eckardt JR, Kuhn JG, et al, "Phase II Trial of Irinotecan in Patients With Progressive or Rapidly Recurrent Colorectal Cancer," <i>J Clin Oncol</i>, 1996, 14(4):1128-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/8648367/pubmed" id="8648367" target="_blank">8648367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26351333">
<a name="26351333"></a>Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline. <i>J Clin Oncol</i>. 2015;33(34):4106-4111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/26351333/pubmed" id="26351333" target="_blank">26351333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandhu.1">
<a name="Sandhu.1"></a>Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N. On behalf of the ADDIKD Guideline Working Group. <i>International consensus guideline on anticancer drug dosing in kidney dysfunction</i>. St. Leonards, Australia: eviQ, Cancer Institute NSW; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16423848">
<a name="16423848"></a>Schmittel A, Fischer von Weikersthal L, Sebastian M, et al, “A Randomized Phase II Trial of Irinotecan Plus Carboplatin Versus Etoposide Plus Carboplatin Treatment in Patients With Extended Disease Small-Cell Lung Cancer,” <i>Ann Oncol</i>, 2006, 17(4):663-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/16423848/pubmed" id="16423848" target="_blank">16423848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23536639">
<a name="23536639"></a>Shiozawa T, Tadokoro J, Fujiki T, et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. <i>Jpn J Clin Oncol</i>. 2013;43(5):483-491. doi:10.1093/jjco/hyt040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/23536639/pubmed" id="23536639" target="_blank">23536639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11893885">
<a name="11893885"></a>Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. <i>Onkologie</i>. 2002;25(1):60-63. doi:10.1159/000055204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/11893885/pubmed" id="11893885" target="_blank">11893885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25877855">
<a name="25877855"></a>Tabernero J, Yoshino T, Cohn AL, et al; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncol</i>. 2015;16(5):499-508. doi:10.1016/S1470-2045(15)70127-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/25877855/pubmed" id="25877855" target="_blank">25877855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33185049">
<a name="33185049"></a>Tate S, Nishikimi K, Matsuoka A, et al. Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial. <i>J Gynecol Oncol.</i> 2021;32(1):e8. doi:10.3802/jgo.2021.32.e8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/33185049/pubmed" id="33185049" target="_blank">33185049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19622957">
<a name="19622957"></a>Taylor J, Amanze A, Di Federico E, Verschraegen C. Irinotecan use during pregnancy. <i>Obstet Gynecol</i>. 2009;114(2 Pt 2):451-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19622957/pubmed" id="19622957" target="_blank">19622957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16809730">
<a name="16809730"></a>Toffoli G, Cecchin E, Corona G, et al, “The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer,” <i>J Clin Oncol</i>, 2006, 24(19):3061-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/16809730/pubmed" id="16809730" target="_blank">16809730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19339720">
<a name="19339720"></a>Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <i>N Engl J Med</i>. 2009;360(14):1408-1417. doi:10.1056/NEJMoa0805019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19339720/pubmed" id="19339720" target="_blank">19339720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502544">
<a name="21502544"></a>Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.<i> J Clin Oncol</i>. 2011;29(15):2011-2019. doi:10.1200/JCO.2010.33.5091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21502544/pubmed" id="21502544" target="_blank">21502544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949147">
<a name="22949147"></a>Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>J Clin Oncol.</i> 2012;30(28):3499-3506. doi:10.1200/JCO.2012.42.8201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/22949147/pubmed" id="22949147" target="_blank">22949147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21216137">
<a name="21216137"></a>van der Bol JM, Loos WJ, de Jong FA, et al, “Effect of Omeprazole on the Pharmacokinetics and Toxicities of Irinotecan in Cancer Patients: A Prospective Cross-Over Drug-Drug Interaction Study,” <i>Eur J Cancer</i>, 2011, 47(6):831-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21216137/pubmed" id="21216137" target="_blank">21216137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17563393">
<a name="17563393"></a>van der Bol JM, Mathijssen RH, Loos WJ, et al, “Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia,” <i>J Clin Oncol</i>, 2007, 25(19):2719-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17563393/pubmed" id="17563393" target="_blank">17563393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17264330">
<a name="17264330"></a>Vassal G, Couanet D, Stockdale E, et al, "Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group," <i>J Clin Oncol</i>, 2007, 25(4):356-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17264330/pubmed" id="17264330" target="_blank">17264330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667606">
<a name="17667606"></a>Vénat-Bouvet L, Saint-Marcoux F, Lagarde C, Peyronnet P, Lebrun-Ly V, Tubiana-Mathieu N. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. <i>Anticancer Drugs</i>. 2007;18(8):977-980. doi:10.1097/CAD.0b013e32811d69cb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17667606/pubmed" id="17667606" target="_blank">17667606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9053486">
<a name="9053486"></a>Verschraegen CF, Levy T, Kudelka AP, et al, “Phase II Study of Irinotecan in Prior Chemotherapy-Treated Squamous Cell Carcinoma of the Cervix,” <i>J Clin Oncol</i>, 1997, 5(2):625-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/9053486/pubmed" id="9053486" target="_blank">9053486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947719">
<a name="17947719"></a>Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al, “Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme,” <i>J Clin Oncol</i>, 2007, 25(30):4722-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17947719/pubmed" id="17947719" target="_blank">17947719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20108333">
<a name="20108333"></a>Wagner LM, "Oral Irinotecan for Treatment of Pediatric Solid Tumors: Ready for Prime Time?" <i>Pediatr Blood Cancer</i>, 2010, 54(5):661-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20108333/pubmed" id="20108333" target="_blank">20108333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17570704">
<a name="17570704"></a>Wagner LM, Crews KR, Stewart CF, et al, "Reducing Irinotecan-Associated Diarrhea in Children," <i>Pediatr Blood Cancer</i>, 2008, 50(2):201-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/17570704/pubmed" id="17570704" target="_blank">17570704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16317751">
<a name="16317751"></a>Wagner LM, McAllister N, Goldsby RE, et al, "Temozolomide and Intravenous Irinotecan for Treatment of Advanced Ewing Sarcoma," <i>Pediatr Blood Cancer</i>, 2007, 48(2):132-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/16317751/pubmed" id="16317751" target="_blank">16317751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20049936">
<a name="20049936"></a>Wagner LM, Perentesis JP, Reid JM, et al, "Phase I Trial of Two Schedules of Vincristine, Oral irinotecan, and Temozolomide (VOIT) for Children With Relapsed or Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Study," <i>Pediatr Blood Cancer</i>, 2010a, 54(4):538-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/20049936/pubmed" id="20049936" target="_blank">20049936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Walker.1">
<a name="Walker.1"></a>Walker SE, Law S, and Puodziunas A, “Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers,” <i>Can J Hosp Pharm</i>, 2005, 58(4): 212-22.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26503200">
<a name="26503200"></a>Weigel BJ, Lyden E, Anderson JR, et al. Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2016;34(2):117-122. doi: 10.1200/JCO.2015.63.4048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/26503200/pubmed" id="26503200" target="_blank">26503200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19088717">
<a name="19088717"></a>Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. <i>Br J Cancer.</i> 2009;100(1):50-55. doi:10.1038/sj.bjc.6604829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/19088717/pubmed" id="19088717" target="_blank">19088717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21425142">
<a name="21425142"></a>Zaanan A, Gauthier M, Malka D, et al; Association des Gastro Entérologues Oncologues. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. <i>Cancer</i>. 2011;117(7):1422-1428. doi:10.1002/cncr.25614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/irinotecan-conventional-drug-information/abstract-text/21425142/pubmed" id="21425142" target="_blank">21425142</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8573 Version 485.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
